Edoxaban: Review of pharmacology and key phase I to III clinical trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 19, Issue 5, 2014, Pages 409-416

  Plitt, Anna ^a   Giugliano, Robert P ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atrial fibrillation; Edoxaban; Factor xa inhibitor; Venous thromboembolism

Indexed keywords

EDOXABAN; WARFARIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANTICOAGULATION; BLOOD CLOT LYSIS; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CREATININE CLEARANCE; DRUG ABSORPTION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL KNEE REPLACEMENT; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ATRIAL FIBRILLATION; CLINICAL TRIAL (TOPIC); COMPLICATION; HEMORRHAGE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VENOUS THROMBOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 84905246056     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248414523675     Document Type: Review

References (46)

1. Services USDoHaH. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. Rockville, MD: US Department of Health and Human Services; 2008.
2. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012; 25(3):235-242.
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 suppl):381S-453S.
4. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37(2):371-378.
5. Partida RA, Giugliano RP. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiol. 2011;7(4):459-470.
6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-891.
7. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidencebased clinical practice guidelines. Chest. 2012;141(2 suppl): e419S-e494S.
8. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: A network meta-analysis of 79 808 patients [published online September 5, 2013.]. Heart. 2013:1-10.
9. Gallego P, Roldan V, Lip GY. Novel oral anticoagulants in cardiovascular disease. J Cardiovasc Pharmacol Ther. 2014;19(1): 34-44.
10. Heidbuchel H, Verhamme P, Alings M, et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625-651.
11. Dewald TA, Becker RC. The pharmacology of novel oral anticoagulants [published online July 17, 2013.]. J Thromb Thrombolysis. 2013.
12. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc. 2013;2(5):e000136.
13. Gonsalves WI, Pruthi RK, Patnaik MM. The new oral anticoagulants in clinical practice. Mayo Clin Proc. 2013;88(5):495-511.
14. Schirmer SH, Baumhäkel M, Neuberger HR, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol. 2010; 56(25):2067-2076.
15. Weitz JI, Eikelboom JW, Samama MM; American College of Chest Physicians. New antithrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 suppl):e120S-e151S.
16. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: A systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381-2391.
17. National Center for Biotechnology Information, U.S.N.L.o.M. edoxaban - Compound Summary. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10280735. Accessed November 9, 2013.
18. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: In vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-1549.
19. Zafar MU, Vorchheimer DA, Gaztanaga J, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007;98:883-888.
20. Camm AJ, Bounameaux H. Edoxaban: A new oral direct factor xa inhibitor. Drugs. 2011;71(12):1503-1526.
21. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-753.
22. Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Am Coll Clin Pharmacol. 2013; 2(4):358-366.
23. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160(4):635-641.
24. Eriksson BI, Quinlan DJ, Weitz JI.Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48(1):1-22.
25. Kubitza D, Becka M, Roth A, Mueck W.Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin, 2008;24(10):2757-265.
26. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.
27. Grip LT, Giugliano RP. Importance of dose selection in novel oral anticoagulants for atrial fibrillation. Arch Cardiol Mex. 2012; 82(4):308-311.
28. Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8(11):2458-2468.
29. Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. a randomised double-blind dose-response study. Thromb Haemost. 2010;104(3):642-649.
30. A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (eTRIS). 2013 [cited 2013 10/24/2013]; http://clinicaltrials.gov/ct2/show/study/NCT01662908?term=edoxaban&phase=1&rank=1 Accessed October 24, 2013.
31. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010; 104(3):633-641.
32. Renda G, De Caterina R. The new oral anticoagulants in atrial fibrillation: once daily or twice daily? Vascul Pharmacol. 2013; 59(3-4):53-62.
33. Fuji T, F.S., Tachibana S, et al, Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-Vtrial. In:American Society of Hematology, 52nd ASH Annual Meeting. Orlando, FL; 2010.
34. Fuji T, Wang CJ, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee replacement. In: The STARS E-3 trial, in 21st International Congress of Thrombosis. Milan, Italy; 2010.
35. Fujita S, FujiT, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemost Thromb. 2010; 37: A95 (P366).
36. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
37. Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415.
38. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369(22):2093-2104.
39. Laliberté F, Nelson WW, Lefebvre P, Schein JR, Rondeau- Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29(8):675-690.
40. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis. 2013;36(2): 187-194.
41. Samama MM, Mendell J, Guinet C, Le Flem L, Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129(4):e77-e82.
42. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26(2):191-202.
43. Fukuda T, Honda Y, Kamisato C, Morishima Y, Shibano T. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents. Thromb Haemost. 2012; 107(2):253-259.
44. Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests. 2013 [cited 2013 Nov 14, 2013]; http://clinicaltrials.gov/ct2/show/study/NCT01758432?term=portola&rank=5. November 14, 2013.
45. Laulicht B, Sasha B, Jiang X, et al. Antidote for New Oral Anticoagulants: Mechanism of Action and Binding Specificity of PER977. In: XXIV Congress of the International Society on Thromsosis and Haemostasis. Netherlands; 2013.
46. Effects of a Single-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban (PER977-P1). 2013; http://clinicaltrials.gov/ct2/show/NCT01826266?term=edoxaban+reverse&rank=1. November 14, 2013.